Repaglinide, but Not Nateglinide Administered Supraspinally and Spinally Exerts an Anti-Diabetic Action in D-Glucose Fed and Streptozotocin-Treated Mouse Models.
10.4196/kjpp.2013.17.6.493
- Author:
Yun Beom SIM
1
;
Soo Hyun PARK
;
Yu Jung KANG
;
Sung Su KIM
;
Chea Ha KIM
;
Su Jin KIM
;
Su Min LIM
;
Jun Sub JUNG
;
Ohk Hyun RYU
;
Moon Gi CHOI
;
Hong Won SUH
Author Information
1. Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University, Chuncheon 200-702, Korea. hwsuh@hallym.ac.kr
- Publication Type:Original Article
- Keywords:
Blood glucose;
Glinides;
Spinal;
Streptozotocin;
Supraspinal
- MeSH:
Animals;
Blood Glucose;
Brain;
Carbamates;
Central Nervous System;
Cyclohexanes;
Glucose*;
Hand;
Insulin;
Mice*;
Mice, Inbred ICR;
Phenylalanine;
Piperidines;
Plasma;
Spinal Cord;
Streptozocin
- From:The Korean Journal of Physiology and Pharmacology
2013;17(6):493-497
- CountryRepublic of Korea
- Language:English
-
Abstract:
We have recently demonstrated that some anti-diabetic drugs such as biguanide and thizolidinediones administered centrally modulate the blood glucose level, suggesting that orally administered anti-diabetic drugs may modulate the blood glucose level by acting on central nervous system. The present study was designed to explore the possible action of another class of anti-diabetic drugs, glinidies, administered centrally on the blood glucose level in ICR mice. Mice were administered intracerebroventricularly (i.c.v.) or intrathecally (i.t.) with 5 to 30 microg of repaglinide or nateglinide in D-glucose-fed and streptozotocin (STZ)-treated models. We found that i.c.v. or i.t. injection with repaglinide dose-dependently attenuated the blood glucose level in D-glucose-fed model, whereas i.c.v. or i.t. injection with nateglinide showed no modulatory action on the blood glucose level in D-glucose-fed model. Furthermore, the effect of repaglinide administered i.c.v. or i.t. on the blood glucose level in STZ-treated model was studied. We found that repaglinide administered i.c.v. slightly enhanced the blood glucose level in STZ-treated model. On the other hand, i.t. injection with repaglinide attenuated the blood glucose level in STZ-treated model. The plasma insulin level was enhanced by repaglinide in D-glucose-fed model, but repaglinide did not affect the plasma insulin level in STZ-treated model. In addition, nateglinide did not alter the plasma insulin level in both D-glucose-fed and STZ-treated models. These results suggest that the anti-diabetic action of repaglinide appears to be, at least, mediated via the brain and the spinal cord as revealed in both D-glucose fed and STZ-treated models.
